Medicenna Therapeutics Corp. Common Shares
MDNA
MDNA was delisted on the 1st of November, 2023.
27 hedge funds and large institutions have $5.6M invested in Medicenna Therapeutics Corp. Common Shares in 2023 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 6 reducing their positions, and 3 closing their positions.
26% more capital invested
Capital invested by funds: $4.43M → $5.6M (+$1.16M)
0% more funds holding
Funds holding: 27 → 27 (0)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
50% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Verition Fund Management
Greenwich,
Connecticut
|
+$40.1K |
| 2 |
Millennium Management
New York
|
+$6.64K |
| 3 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
+$6.48K |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$3.04K |
| 5 |
Wells Fargo
San Francisco,
California
|
+$445 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alyeska Investment Group
Chicago,
Illinois
|
-$298K |
| 2 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$68.7K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$22.8K |
| 4 |
VF
Virtu Financial
New York
|
-$20K |
| 5 |
Renaissance Technologies
New York
|
-$16.3K |
MDNA Hedge Fund Activity: Q1 2023 in Review
27 of the 6,276 institutional investors tracked by Wall St. Rank reported a position in Medicenna Therapeutics Corp. Common Shares (MDNA) for Q1 2023, worth a combined $5.6M — up 26% from $4.43M a quarter earlier.
Fund positioning in MDNA was balanced in Q1 2023: 3 funds opened new positions, 3 closed out, 3 added to existing stakes and 6 trimmed.
The largest buyer was Verition Fund Management, adding an estimated $40.1K. The largest seller was Alyeska Investment Group, exiting entirely with an estimated $298K sold.
- 27 institutional investors held Medicenna Therapeutics Corp. Common Shares (MDNA) as of Q1 2023, unchanged from Q4 2022.
- Funds reported $5.6M of Medicenna Therapeutics Corp. Common Shares stock for Q1 2023, up 26% quarter-over-quarter.
- 3 funds opened new Medicenna Therapeutics Corp. Common Shares positions in Q1 2023 and 3 closed out, a net change of 0 holders.
- The largest Medicenna Therapeutics Corp. Common Shares buyer in Q1 2023 was Verition Fund Management, an estimated $40.1K added.
- The largest Medicenna Therapeutics Corp. Common Shares seller in Q1 2023 was Alyeska Investment Group, an estimated $298K sold.
Based on aggregated 13F filings for Q1 2023.